Management of a Patient with HIV-HCV Coinfection and Substance Use DisorderPremiere Date: Wednesday, December 4, 2019
This activity offers CE credit for:%>
- Physicians (CME)
- Pharmacists (ACPE)
- ABIM (MOC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, December 31, 2020
Note: Credit Is No Longer Available
|David Alain Wohl, MD
Professor of Medicine
Institute of Global Health and Infectious Diseases
Site Leader, Global Infectious Diseases Clinical Trials Unit, Chapel Hill Site
The University of North Carolina (UNC) at Chapel Hill School of Medicine
Chapel Hill, NC
|Carlos Malvestutto, MD, MPH
Division of Infectious Diseases
Department of Medicine
Ohio State University Wexner Medical Center
|Jaimie P. Meyer, MD, MS, FACP
Assistant Professor of Medicine
Department of Internal Medicine, Section of Infectious Disease AIDS Program
Yale University School of Medicine
Clinical Assistant Professor
Division of Primary Care/Health Systems in Nursing
Yale School of Nursing
New Haven, CT
The Centers for Disease Control and Prevention (CDC) reported that there was a 233% increase in new HCV infections between 2010-2016, and there is a high rate of HIV/HCV co-infection among individuals with substance use disorder who practice injection drug use (IDU). This underscores the need for improved HIV and HCV testing and care, particularly for those with substance use disorder.
The final installment of this three-part CME Outfitters Briefcase, a case-based faculty interview, features expert faculty discussing implementation of team-based approaches for the management of patients with HIV-HCV confection and substance use disorder in order to improve care for these patients.
At the end of this CE activity, participants should be able to:
- Implement team-based approaches for the management of patients with HIV-HCV coinfection and substance use disorder.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Explain team-based approaches for the management of patients with HIV-HCV coinfection and substance use disorder.
Supported by an educational grant from Gilead Sciences, Inc.
OUD specialists, primary care physicians, psychiatrists, mental health specialists, physician assistants, nurse practitioners, and pharmacists.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.5 contact hours (0.05 CEUs) Universal Activity Number:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners practicing in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Wohl reports that he receives research support from Gilead Sciences, Inc.; Merck & Co., Inc.; and ViiV Healthcare. He is on the advisory committee for Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; and ViiV Healthcare. He is a consultant for Gilead Sciences, Inc.
Dr. Malvestutto reports that he is on the advisory committee for ViiV Healthcare.
Dr. Meyer reports that she receives research support from Gilead Sciences, Inc.
Tony Graham, MD (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Kavitha Ramachandran, PhD (planning committee) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).